Patients with renal cancer have immunosuppressive CD14−CD15+CD11b+CD66b+ granulocytic MDSCs 20], whereas CD14+HLA-DR−/low monocytic MDSCs circulate in the blood of patients with melanoma, multiple myeloma, prostate cancer, hepatocellular carcinoma or head and neck cancer 21–24]. Here, ITGAM is linked to renal carcinoma.